CorMedix Inc. Annual Report - A Transformative Year (Fiscal Year Ended December 31, 2025)

CorMedix Inc. (CRMD) experienced a pivotal and transformative year ending December 31, 2025. This summary provides a clear overview of the company's business, financial performance, and strategic direction, offering key insights for investors.

Business Overview

CorMedix is a biopharmaceutical company that develops and commercializes products for serious diseases, focusing on infectious diseases and oncology support. Its flagship product, DefenCath, is an antimicrobial catheter lock solution designed to prevent serious bloodstream infections. In 2025, CorMedix significantly expanded its product portfolio and commercial capabilities by acquiring Melinta Therapeutics, which added established infectious disease and cardiovascular products. The company aims to address unmet medical needs through its innovative pipeline and strategic growth initiatives.

The Big Picture: Financials & Strategic Growth

CorMedix's significant expansion in 2025 stemmed from a major product launch and a strategic acquisition.

• Total Revenue: CorMedix reported a substantial increase in total revenue for 2025 from the prior year. This growth primarily resulted from DefenCath's commercial launch and the Melinta acquisition.
• Net Loss: The company posted a net loss due to significant investments in commercialization, research and development, and acquisition-related expenses.
• Cash Position: CorMedix ended the year with a strengthened cash and equivalents position, boosted by acquisition financing.

Two key developments fueled this growth:

1. DefenCath's successful market entry, which quickly became a primary revenue driver.
2. The August 2025 acquisition of Melinta Therapeutics, which significantly expanded CorMedix's product portfolio and commercial footprint.

DefenCath: Their Flagship Product Takes Off

• What it is: DefenCath is a specialized antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs)—serious bloodstream infections—in adult kidney failure patients undergoing long-term hemodialysis via a central venous catheter.
• Why it's important: CRBSIs pose a significant healthcare burden, causing high costs, hospitalizations, and mortality. DefenCath addresses a critical unmet need as the first FDA-approved preventative treatment for this specific patient population.
• Performance & Impact:
  • The FDA approved DefenCath in November 2023. It launched commercially in April 2024 (hospitals) and July 2024 (outpatient dialysis centers).
  • It generated significant net product sales in 2025, contributing substantially to total company revenue.
  • Clinical studies demonstrated up to a 71% reduction in CRBSI risk. December 2025 real-world data further highlighted a 70% reduction in hospitalizations from these infections, underscoring DefenCath's significant clinical and economic value.
  • Commercial reach is strong; contracts cover approximately 60% of U.S. outpatient dialysis centers.

Navigating Reimbursement for DefenCath: A Key Challenge

Reimbursement mechanisms are crucial for DefenCath's profitability:

• For Hospitals (Inpatient): DefenCath receives a New Technology Add-on Payment (NTAP) from Medicare, covering up to 75% of its cost. This NTAP expires on November 14, 2026. After expiration, hospitals' reimbursement for DefenCath will likely decrease, potentially impacting CorMedix's net selling price.
• For Dialysis Clinics (Outpatient): Medicare's Transitional Drug Add-on Payment Adjustment (TDAPA) has supported DefenCath sales since July 2024. However, this payment will likely decline significantly by approximately 70-80% starting July 1, 2026, for the remainder of the year. CorMedix anticipates a material reduction in DefenCath's net selling price and revenue during this period.
  • Potential Rebound: The company projects the 2027 payment rate could be 3 to 5 times higher than the reduced late-2026 rate, offering potential recovery. However, this is not guaranteed and depends on future Medicare rate-setting.
• Other Outpatient Settings: DefenCath also secured "pass-through" status in June 2024 for certain outpatient hospital settings. This ensures separate payment for at least two to three years and supports broader adoption.

Expanding DefenCath's Horizon

CorMedix is actively pursuing new indications for DefenCath:

• Total Parenteral Nutrition (TPN) Patients: CorMedix initiated a Phase 3 clinical trial in mid-2025 to evaluate DefenCath for CRBSI prevention in adult TPN patients. This represents a substantial market opportunity, estimated at $500 million to $750 million annually. Results are anticipated in the first half of 2027.
• Pediatric Dialysis Patients: A study for pediatric dialysis patients began in 2025. Successful completion could grant DefenCath an additional six months of U.S. market exclusivity.

The Melinta Therapeutics Acquisition: A Strategic Leap

CorMedix acquired Melinta Therapeutics in August 2025 for a significant amount in cash and stock. This transformative event significantly expanded CorMedix's scale and market presence.

• Expanded Portfolio: CorMedix now boasts a broader product portfolio, including six established infectious disease products (notably REZZAYO, MINOCIN IV, and VABOMERE, which generated substantial combined sales post-acquisition) and the cardiovascular product TOPROL-XL.
• Enhanced Commercial Infrastructure: The acquisition brought a seasoned sales and commercial team, significantly strengthening CorMedix's reach into hospitals and clinics and increasing its sales force significantly.
• Synergies: Melinta's anti-infective products align well with DefenCath, creating cross-selling opportunities and allowing a more comprehensive offering to healthcare providers.

Competitive Position

CorMedix operates in highly competitive biopharmaceutical markets.

• DefenCath: DefenCath holds a unique competitive position as the first and only FDA-approved antimicrobial catheter lock solution specifically indicated for preventing CRBSIs in adult hemodialysis patients with a central venous catheter. Its clinical efficacy in reducing infections and hospitalizations provides a significant advantage. While other catheter lock solutions or systemic antibiotics exist, none share DefenCath's specific indication or demonstrated preventative profile. The company relies on its intellectual property and regulatory exclusivity to maintain this competitive edge.
• Melinta Products: The acquired Melinta portfolio—including REZZAYO, MINOCIN IV, and VABOMERE—competes in the established infectious disease market. These products face competition from other branded and generic antibiotics. Competitive factors include product efficacy, safety, ease of administration, cost, and reimbursement. CorMedix leverages these products' established market presence and clinical profiles, combined with its expanded commercial infrastructure, to compete effectively. The company's overall strategy differentiates through clinical value, commercial reach, and a focused approach to infectious disease management.

Management's Discussion and Analysis (MD&A) Highlights

Financial Performance (Results of Operations) For the fiscal year ended December 31, 2025, CorMedix achieved significant revenue growth. This growth primarily stemmed from DefenCath's commercial launch and the partial-year contribution from the Melinta Therapeutics acquisition. The substantial revenue increase reflects successful market penetration for DefenCath and the immediate impact of integrating Melinta's established product sales. Despite this growth, the company reported a net loss. This loss largely resulted from increased operating expenses associated with DefenCath's commercialization, including sales and marketing activities, and the integration costs and ongoing research and development investments related to the expanded pipeline from the Melinta acquisition. The company's strategic investments in commercial infrastructure and pipeline expansion position it for future growth, though they impacted short-term profitability.

Financial Health (Liquidity and Capital Resources) CorMedix ended 2025 with a strengthened cash and equivalents position, boosted by financing activities related to the Melinta acquisition. The company funded the acquisition through a combination of cash and stock. Its primary sources of liquidity include cash and cash equivalents, and potential future product sales. The company anticipates its current cash resources, combined with anticipated revenues, will fund operations for at least the next 12 months. However, future capital raises may be required to support ongoing commercialization efforts, pipeline development, and potential future strategic transactions. The company manages its debt obligations, primarily related to the Melinta acquisition.

Critical Accounting Estimates Preparing financial statements under U.S. GAAP requires management to make estimates and judgments affecting reported amounts of assets, liabilities, revenue, and expenses. Key areas requiring significant estimates include revenue recognition (especially for product sales with complex reimbursement and rebate programs like DefenCath), valuation of acquired intangible assets and goodwill from the Melinta acquisition, and accounting for stock-based compensation. These estimates rely on historical experience and various assumptions believed to be reasonable, but actual results could differ.

Future Outlook

CorMedix's strategy focuses on maximizing its expanded portfolio and pipeline:

• Optimize Commercial Performance: Drive sales growth for DefenCath and key Melinta products (REZZAYO, MINOCIN IV, VABOMERE). This involves leveraging the integrated commercial team, expanding market penetration, navigating anticipated DefenCath reimbursement changes in 2026, and working towards favorable reimbursement outcomes in 2027 and beyond.
• Pipeline Expansion: Advance DefenCath into new indications (TPN, pediatric dialysis) to unlock significant additional market opportunities and extend market exclusivity. The company also plans to explore additional uses for REZZAYO.
• Strategic Business Development: Continuously evaluate opportunities for in-licensing, partnerships, or further acquisitions. These efforts aim to enhance the product pipeline and market position, particularly in infectious diseases and oncology support, aligning with CorMedix's core therapeutic areas.

Risk Factors

While the outlook is promising, investors should be aware of several risks:

• DefenCath Reimbursement Changes: The anticipated significant decline in Medicare reimbursement rates for DefenCath in late 2026 poses a material risk to revenue and profitability, despite potential 2027 recovery. The company's ability to mitigate this impact through commercial strategies and advocacy efforts is critical.
• Competition: The highly competitive biopharmaceutical market means existing and emerging treatments could impact market share for DefenCath and Melinta's products. New product introductions or advancements by competitors could erode market share or pricing power.
• Clinical Trial Success: Success for ongoing DefenCath trials (TPN, pediatric) is not guaranteed. Trial failures or delays could impact future growth, market exclusivity, and investor confidence.
• Regulatory Landscape: Changes in FDA regulations, unexpected adverse events, or delays in new product approvals could affect market access and product viability. Extensive government regulation applies to the company.
• Melinta Integration: Successfully integrating Melinta's operations, products, and personnel is crucial for realizing anticipated synergies and financial benefits. Integration challenges could arise, impacting operational efficiency and financial performance.
• Intellectual Property: Protecting DefenCath's and other products' intellectual property is vital for long-term market exclusivity and competitive advantage. Challenges to patents or the emergence of generic alternatives could significantly impact future revenues.
• Product Liability: As a pharmaceutical company, CorMedix faces inherent product liability risks. Claims could result in significant financial costs and reputational damage.
• Dependence on Third Parties: The company relies on third parties for manufacturing, distribution, and certain clinical trial activities, exposing it to risks of supply chain disruptions, quality control, and compliance.

In a Nutshell:

2025 proved a transformative year for CorMedix, marked by DefenCath's successful launch and the strategic acquisition of Melinta Therapeutics. The company emerged as a larger, more diversified biopharmaceutical entity with a strong commercial presence and pipeline. While navigating the upcoming DefenCath reimbursement changes in 2026 presents a critical challenge, CorMedix actively works to expand its product's reach and leverage its enhanced portfolio for sustained growth. Investors should closely watch the financial impact of reimbursement shifts, the progress of its clinical pipeline, and the successful integration of Melinta.